News | May 07, 2026
Neuland Labs and LIR Life partner on next-gen transdermal GLP-1 obesity therapy platform
LIR Life is working on a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity
LIR Life is working on a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity
Approval strengthens the company’s growing international anti-infective portfolio
The 40-second film brings children to the forefront of the narrative
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
The company informed stock exchanges that the appellate authority has set aside the GST demand along with applicable interest and penalty
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
Subscribe To Our Newsletter & Stay Updated
